| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Derek Simmross CEO | XSTO Exchange | SE0013409760 ISIN |
| SE Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
ODI Pharma AB (publ) emerged as a noteworthy player in the pharmaceutical industry by specializing in the production and distribution of pharmaceutical cannabis and cosmetic products across Europe. With the company's inception in 2018, it made its mark from its headquarters in Stockholm, Sweden. Dedicating itself to delivering high-quality products that leverage the therapeutic potential of cannabidiol (CBD), ODI Pharma has positioned itself at the intersection of health and wellness, catering to a growing demand for cannabis-based pharmaceuticals and skincare solutions.
All of these products are marketed under the Kandol. brand name and are available for purchase through their dedicated website, kandol.net.